ABO2011 + toripalimab

ABO2011 + toripalimab is an investigational combination therapy for advanced solid tumors. ABO2011 is a novel IL-12 stimulant (immune agonist), while toripalimab is a monoclonal antibody that targets and inhibits PD-1 (programmed cell death protein 1) on T cells. The combination is being studied for its ability to enhance anti-tumor immune responses. The rationale for combining these agents is that IL-12 agonism can increase anti-tumor immunity, and PD-1 blockade can further relieve tumor-mediated immune suppression, potentially resulting in synergistic anti-cancer effects. The combination is currently being evaluated in Phase 1/2 clinical trials to determine safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy in patients with advanced solid tumors[1][2].